Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.
Syed Rizvi, MD
Advertisement
Articles by Syed Rizvi, MD
Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.
Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.
Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin LymphomaPublished: February 11th 2020 | Updated:
Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin LymphomaPublished: March 19th 2020 | Updated:
Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin LymphomaPublished: April 16th 2020 | Updated:
Dr. Rizvi on the Limitations of ABVD in Hodgkin LymphomaPublished: April 24th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5